[Editor's Note: Our Antidote partner, Precision Medicine for Me, continues to expand their reach into the cancer community. If you enjoy the following article, we also suggest e-Patient, Dave deBronkart's blog, 4-year lung cancer survivor, Francisco Millán's story, Janet Freeman-Daily's video, and Antidote's Director of Communications, Lisa Conroy's, insightful blog.]
In the next decade, a lot will change. We’ll see driverless cars become commonplace, and our neighbors may become tourists in outer space. But one thing’s for sure—the cancer landscape will be completely different than it is today.
In ten years’ time, current research will have transformed the prognosis for many cancers. Cancer could become a universally chronic condition—or even a curable one. While we can’t predict this transformation, we do know one thing: there will be a lot of new information out there, and many new treatment options.
That’s why we’ve launched the Precision Medicine for Me initiative. It’s a collaboration of more than a dozen patient organizations, patient advocates, startups, and industry leaders with a singular goal: to inspire and help patients understand and navigate the potential of new tumor testing, and raise awareness of the latest treatments and trials. We’re starting with a focus on lung cancer, and will be branching out to include other cancers in the future.
Understanding and navigating this new testing means making sure patients get the right test at the right time to learn more about their particular type of cancer, now or in the future. Our aim is to educate patients on the importance of getting their tumors tested appropriately, so that with their healthcare team, they are armed with the knowledge to explore all treatment options—including those that are already approved, approved for a different use, or still in development.
About Precision Medicine
This is a complex mission, to be sure. Even at this early stage we recognize that, educational efforts aside, the level of promise in currently available testing depends on where a patient lives, and whether they can travel to a major cancer center. We know that this testing is expensive. Facing these issues head-on as part of our lung cancer pilot, our partners at the Lung Cancer Alliance have launched a program through which patients can call and be connected to tumor testing as close to them as possible. As we move forward with the Precision Medicine for Me initiative, we will continue to work collaboratively to put other programs in place to tackle additional issues as they arise. We’d love hear your perspective on what the biggest issues are—please feel free to email us at email@example.com with any thoughts there.
In periods of rapid medical progress, patient empowerment can make all the difference. We can’t promise that tumor testing will lead to a successful treatment for everyone. What we can promise is that Precision Medicine for Me is dedicated to getting patients access to what the world is learning and discovering in cancer so they can act on that information today.
To learn more about this initiative, please visit www.precision-medicine.me.